Efficacy of Combined Treatment with Lanreotide and Cabergoline in Selected Therapy-Resistant Acromegalic Patients

Pituitary

Volumn 1, Issue 2, 1999, Pages 115-120

  Marzullo, Paolo ^a   Ferone, Diego ^a   Di Somma, Carolina ^a   Pivonello, Rosario ^a   Filippella, Mariagiovanna ^a   Lombardi, Gaetano ^a   Colao, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Acromegaly; Cabergoline; Dopamine agonists; GH; IGF I; Lanreotide; Octreotide; Quinagolide; Somatostatin analogs

Indexed keywords

AMINOQUINOLINE DERIVATIVE; ANGIOPEPTIN; CABERGOLINE; CYCLOPEPTIDE; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; ERGOLINE DERIVATIVE; HORMONE; HUMAN GROWTH HORMONE; OCTREOTIDE; QUINAGOLIDE; SOMATOMEDIN C; SOMATOSTATIN;

ACROMEGALY; ADULT; ARTICLE; BLOOD; COMPARATIVE STUDY; DRUG COMBINATION; DRUG POTENTIATION; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; TIME;

ACROMEGALY; ADULT; AMINOQUINOLINES; DOPAMINE AGONISTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ERGOLINES; FEMALE; HORMONES; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PEPTIDES, CYCLIC; SOMATOSTATIN; TIME FACTORS;

EID: 0033288398     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009932521242     Document Type: Article

References (29)

1. Melmed S. Acromegaly. N Engl J Med 1990;322:966-977.
2. Frohman LA. Therapeutic options in acromegaly. J Clin Endocrinol Metab 1991;72:1175-1181.
3. Melmed S, Ho K, Klibanski A, Reinchlin S, Thorner M. Recent advances in pathology, diagnosis and management of acromegaly. J Clin Endocrinol Metab 1995;80:3395-3402.
4. Colao A, Merola B, Ferone D, Lombardi G. Acromegaly. J Clin Endocrinol Metab 1997;84:2777-2781.
5. Melmed S, Bowling H, Frohman L, et al. Consensus statement: benefits versus risks of medical therapy for acromegaly. Am J Med 1994;97:468-473.
6. Lamberts SWJ, van Der Lely AJ, de Herder WW, Hofland J. Octreotide. N Engl J Med 1996;334:246-254.
7. Heron I, Thomas F, Dero M, et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 1993;76:721-727.
8. Chiodini PG, Attanasio R, Cozzi R, et al. CV 205-502 in acromegaly. Acta Endocrinol 1993;128:389-393.
9. Ferrari C, Paracchi A, Romano C, et al. Long-lasting lowering of serum growth hormone and prolactin levels by single or repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin Endocrinol 1988;29:467-476.
10. Lamberts SWJ, Zweens M, Verschoor L, del Pozo E. A comparison among the growth hormone lowering effect of the somatostatin analog, SMS 201-995, bromocriptine and combination of both drugs. J Clin Endocrinol Metab 1986;63:16-19.
11. Chiodini PG, Cozzi R, Dallabonzana D, et al. Medical treatment of acromegaly with SMS 201-995, a somatostatin analogue: a comparison with bromocriptine. J Clin Endocrinol Metab 1987;64:447-453.
12. Fløgstad AK, Halse J, Grass P, et al. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J Clin Endocrinol Metab 1994;79:461-465.
13. Morange I, De Boisvilliers F, Chanson P, et al. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 1994; 79:145-151.
14. Marek J, Hana V, Krsek M, Justova V, Catus F, Thomas F. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur J Endocrinol 1994;131:20-26.
15. Giusti M, Gussoni G, Cuttica CM, Giordano G, and the Italian multicenter slow release lanreotide study group. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on a Italian multicenter study. J Clin Endocrinol Metab 1996;81:2089-2097.
16. Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three years follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997; 82:18-22.
17. Lombardi G, Colao A, Ferone D, et al. CV 205-502 treatment in therapy-resistant acromegalic patients. Eur J Endocrinol 1995;132:559-564.
18. Fredstorp L, Kutz K, Werner S. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study. Clin Endocrinol 1994; 41:103-108.
19. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994;331:904-909.
20. Colao A, Di Sarno A, Sarnacchiaro F, et al. Prolactinomas resistant to other dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997; 83:876-883.
21. Jackson SN, Fowler J, Howlett TA. Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin Endocrinol Oxf 1997;46:745-749.
22. Abs R, Versholst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998;83:374-378.
23. Colao A, Ferone D, Lastoria S, et al Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab. 1996;81:1356-1362.
24. Wass JAH. Acromegaly: treatment after 100 years. Br Med J 1993;307:1505-1506.
25. Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, Sandler HM. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab. 1997;82:3187-3191.
26. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992;13:220-240.
27. Colao A, Ferone D, Marzullo P, et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997;82:518-523.
28. Lamberts SWJ, Liuzzi A, Chiodini PG, Verde S, Klijn JGM, Birkenhäger JC. The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly. Eur J Clin Invest 1982;12:151-155.
29. Lamberts SWJ, Klijn JGM, van Vroonhoven CCJ, Stefanko SZ, Liuzzi A. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly. Acta Endocrinol 1983;103:446-450.